ReviewBlood reviews2022
No apparent association between mRNA COVID-19 vaccination and venous thromboembolism.
Review in Blood reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Vasectomy in the absence of paternity A pre- and post-pandemic Canadian cohort analysis.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026Article
- GP Consultations for Venous Thromboembolism (VTE) After mRNA and Adeno-Vector-Based COVID-19 Vaccination-An Exposure-Anchored Self-Controlled Cohort Study Based on Primary Healthcare Data From the Netherlands.Pharmacoepidemiology and drug safety · 2026Article
- Article
- Acute extensive pulmonary embolism after mRNA SARS-CoV-2 immunization.Radiology case reports · 2024Article
- Toxicologic Pathology Forum: mRNA Vaccine Safety-Separating Fact From Fiction.Toxicologic pathology · 2024Article
- Persistently High Platelet Factor 4 Levels in an Adolescent with Recurrent Late Thrombotic Complications after SARS-CoV-2 mRNA Vaccination.Hematology reports · 2024Article
- Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines.NPJ vaccines · 2024Article
- Venous Thromboembolism Following COVID-19 Vaccination in Patients With Hereditary Protein S Deficiency.Journal of hematology · 2024Article
- Effect of SARS-CoV-2 Infection and BNT162b2 Vaccination on the mRNA Expression of Genes Associated with Angiogenesis.International journal of molecular sciences · 2023Article
- Cerebrovascular Disease in COVID-19.Viruses · 2023Review
- Response to "Polyradiculitis Complicating SARS-CoV-2 Vaccinations is Not Infrequent".The Neurohospitalist · 2023Article
- Hematological Questions in Personalized Management of COVID-19 Vaccination.Journal of personalized medicine · 2023Review
- Effect of anti-SARS-CoV-2 BNT162b2 mRNA vaccination on thrombin generation in children with inflammatory bowel disease.Frontiers in immunology · 2023Observational
- Portal vein thrombosis after second Pfizer/BioNTech coronavirus disease 2019 vaccine.Journal of vascular surgery cases and innovative techniques · 2022Article
- Platelet and extracellular vesicles in COVID-19 infection and its vaccines.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Review
- Which type of vaccine is more beneficial for reducing the risk of deep vein thrombosis, CoronaVac, BNT162b2, or TURKOVAC?Science progressArticle
- Anti-PF4 antibodies and their relationship with COVID infection.Hematology, transfusion and cell therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
By January 2022 over ten billion doses of COVID-19 vaccines had been administered worldwide. Concerns about COVID-19 vaccine-associated thrombosis arose after the characterization of a rare prothrombotic condition associated with adenoviral vector-based COVID-19 vaccines known as vaccine-induced immune thrombotic thrombocytopenia (VITT). Although mRNA COVID-19 vaccines have not been linked to VITT, concerns about thrombosis after vaccination persist despite safety data from hundreds of millions of recipients of mRNA COVID-19 vaccines. With widespread vaccination some VTE will occur shortly after vaccination by chance alone because VTE is a common condition that affects 1 to 2 in 1000 persons each year. Detailed analysis is required to determine whether these VTE events are coincidental or associated when they occur in close proximity to mRNA vaccine administration. This paper will review what is currently known about rates of VTE after mRNA vaccination in adults, discuss the reasons why uncertainty on this topic persists, and briefly review the implications of these findings for clinical practice and health policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.